Mackenzie Financial Corp Has $180.37 Million Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Mackenzie Financial Corp lifted its holdings in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 0.6% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 977,073 shares of the medical research company's stock after buying an additional 5,805 shares during the quarter. Mackenzie Financial Corp owned about 1.91% of Charles River Laboratories International worth $180,368,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. D1 Capital Partners L.P. acquired a new stake in Charles River Laboratories International in the fourth quarter worth about $172,752,000. Norges Bank acquired a new stake in Charles River Laboratories International in the fourth quarter worth about $98,886,000. Wellington Management Group LLP increased its position in Charles River Laboratories International by 9.0% in the fourth quarter. Wellington Management Group LLP now owns 4,076,426 shares of the medical research company's stock worth $752,508,000 after purchasing an additional 335,658 shares during the period. Nomura Holdings Inc. acquired a new stake in Charles River Laboratories International in the fourth quarter worth about $56,820,000. Finally, Raymond James Financial Inc. acquired a new stake in Charles River Laboratories International in the fourth quarter worth about $42,776,000. 98.91% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Robert W. Baird boosted their target price on Charles River Laboratories International from $118.00 to $140.00 and gave the stock a "neutral" rating in a research report on Thursday, May 8th. Citigroup upgraded Charles River Laboratories International from a "sell" rating to a "neutral" rating and boosted their target price for the stock from $155.00 to $175.00 in a research report on Tuesday, March 4th. Mizuho cut their price objective on Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating on the stock in a report on Wednesday, April 9th. Barclays lifted their price objective on Charles River Laboratories International from $145.00 to $155.00 and gave the company an "equal weight" rating in a report on Thursday, May 8th. Finally, Morgan Stanley cut their price objective on Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating on the stock in a report on Wednesday, February 5th. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Hold" and an average price target of $171.85.

Insider Buying and Selling

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 500 shares of the company's stock in a transaction on Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total value of $72,705.00. Following the transaction, the executive vice president now directly owns 19,513 shares of the company's stock, valued at $2,837,385.33. This represents a 2.50% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 1.30% of the stock is owned by insiders.

Charles River Laboratories International Stock Up 1.5%

Shares of Charles River Laboratories International stock traded up $2.09 on Tuesday, reaching $138.82. 800,873 shares of the company were exchanged, compared to its average volume of 993,202. Charles River Laboratories International, Inc. has a one year low of $91.86 and a one year high of $254.15. The company has a market capitalization of $6.82 billion, a price-to-earnings ratio of 925.47, a PEG ratio of 4.54 and a beta of 1.50. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. The company has a 50-day moving average of $131.30 and a 200 day moving average of $162.22.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, topping analysts' consensus estimates of $2.06 by $0.28. The business had revenue of $984.17 million for the quarter, compared to analyst estimates of $942.34 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The firm's revenue was down 2.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.27 EPS. On average, equities research analysts forecast that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).